Institution
Mayo Clinic
Healthcare•Rochester, Minnesota, United States•
About: Mayo Clinic is a healthcare organization based out in Rochester, Minnesota, United States. It is known for research contribution in the topics: Population & Transplantation. The organization has 63387 authors who have published 169578 publications receiving 8114006 citations.
Topics: Population, Transplantation, Cancer, Breast cancer, Heart failure
Papers published on a yearly basis
Papers
More filters
••
Boston Children's Hospital1, University of California, San Diego2, University of California, San Francisco3, Oregon Health & Science University4, Northwestern University5, University of Tennessee Health Science Center6, University of British Columbia7, Children's Memorial Hospital8, New York University9, Case Western Reserve University10, Mayo Clinic11, Wake Forest University12, University of Pennsylvania13, University of Nottingham14, University of Alabama at Birmingham15, Rafael Advanced Defense Systems16, American Academy of Dermatology17, Seattle Children's18
TL;DR: Treatment of atopic dermatitis with nonpharmacologic interventions and pharmacologic topical therapies are reviewed and suggestions on dosing and monitoring are given based on available evidence.
Abstract: Atopic dermatitis is a common and chronic, pruritic inflammatory skin condition that can affect all age groups. This evidence-based guideline addresses important clinical questions that arise in its management. In this second of 4 sections, treatment of atopic dermatitis with nonpharmacologic interventions and pharmacologic topical therapies are reviewed. Where possible, suggestions on dosing and monitoring are given based on available evidence.
889 citations
••
TL;DR: In the United States, an estimated 20,000 new cases of liver and biliary tract cancer are diagnosed annually as mentioned in this paper, which is the second most common primary hepatobiliary cancer after hepatocellular cancer.
Abstract: In the United States, an estimated 20,000 new cases of liver and biliary tract cancer are diagnosed annually.1 Biliary tract cancer is the second most common primary hepatobiliary cancer, after hepatocellular cancer. Approximately 7500 new cases of biliary tract cancer are diagnosed per year; about 5000 of these are gallbladder cancer, and between 2000 and 3000 are bile-duct cancers.1 Biliary tract cancers have traditionally been divided into cancers of the gallbladder, the extrahepatic bile ducts, and the ampulla of Vater, whereas intrahepatic bile-duct cancers have been classified as primary liver cancers.2 The term “cholangiocarcinoma” was originally intended to refer only . . .
889 citations
••
Harvard University1, Icahn School of Medicine at Mount Sinai2, Houston Methodist Hospital3, Riverside Methodist Hospital4, Duke University5, The Texas Heart Institute6, Detroit Medical Center7, University of Pittsburgh8, Johns Hopkins University9, United States Department of Veterans Affairs10, University of Michigan11, Baylor College of Medicine12, Erasmus University Rotterdam13, Medtronic plc14, Mayo Clinic15
TL;DR: TAVR with a self-expanding bioprosthesis was safe and effective in patients with symptomatic severe aortic stenosis at prohibitive risk for surgical valve replacement.
888 citations
••
TL;DR: Alcohol and smoking were significant risk factors for the prevalence of Barrett's esophagus in an adult Swedish population and the prevalence in the general population was found to be 1.6% of the general Swedish population.
888 citations
••
TL;DR: A newly identified member of the human B7 family, designated B7 homolog 3 (B7-H3), that shares 20–27% amino acid identity with other B7family members is described, that may participate in the regulation of cell-mediated immune responses.
Abstract: We describe here a newly identified member of the human B7 family, designated B7 homolog 3 (B7-H3), that shares 20-27% amino acid identity with other B7 family members. B7-H3 mRNA is not detectable in peripheral blood mononuclear cells, although it is found in various normal tissues and in several tumor cell lines. Expression of B7-H3 protein, however, can be induced on dendritic cells (DCs) and monocytes by inflammatory cytokines and a combination of phorbol myristate acetate (PMA) + ionomycin. Soluble B7-H3 protein binds a putative counter-receptor on activated T cells that is distinct from CD28, cytotoxic T lymphocyte antigen 4 (CTLA-4), inducible costimulator (ICOS) and PD-1. B7-H3 costimulates proliferation of both CD4+ and CD8+ T cells, enhances the induction of cytotoxic T cells and selectively stimulates interferon gamma (IFN-gamma) production in the presence of T cell receptor signaling. In contrast, inclusion of antisense B7-H3 oligonucleotides decreases the expression of B7-H3 on DCs and inhibits IFN-gamma production by DC-stimulated allogeneic T cells.Thus, we describe a newly identified costimulatory pathway that may participate in the regulation of cell-mediated immune responses.
887 citations
Authors
Showing all 64325 results
Name | H-index | Papers | Citations |
---|---|---|---|
Eugene Braunwald | 230 | 1711 | 264576 |
Peter Libby | 211 | 932 | 182724 |
Cyrus Cooper | 204 | 1869 | 206782 |
Rob Knight | 201 | 1061 | 253207 |
Robert M. Califf | 196 | 1561 | 167961 |
Eric J. Topol | 193 | 1373 | 151025 |
Dennis W. Dickson | 191 | 1243 | 148488 |
Gordon B. Mills | 187 | 1273 | 186451 |
Julie E. Buring | 186 | 950 | 132967 |
Patrick W. Serruys | 186 | 2427 | 173210 |
Cornelia M. van Duijn | 183 | 1030 | 146009 |
Paul G. Richardson | 183 | 1533 | 155912 |
John C. Morris | 183 | 1441 | 168413 |
Valentin Fuster | 179 | 1462 | 185164 |
Ronald C. Petersen | 178 | 1091 | 153067 |